1. Home
  2. CLLS vs INGN Comparison

CLLS vs INGN Comparison

Compare CLLS & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.33

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.49

Market Cap

175.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLLS
INGN
Founded
1999
2001
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
384.3M
175.6M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
CLLS
INGN
Price
$3.33
$6.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$8.50
$11.00
AVG Volume (30 Days)
49.0K
291.0K
Earning Date
03-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.42
EPS
N/A
N/A
Revenue
N/A
$348,668,000.00
Revenue This Year
N/A
$7.92
Revenue Next Year
N/A
$7.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.86
52 Week Low
$1.10
$5.34
52 Week High
$5.48
$9.13

Technical Indicators

Market Signals
Indicator
CLLS
INGN
Relative Strength Index (RSI) 41.25 56.72
Support Level $3.32 $6.25
Resistance Level $3.83 $6.83
Average True Range (ATR) 0.21 0.23
MACD -0.01 0.03
Stochastic Oscillator 17.76 71.97

Price Performance

Historical Comparison
CLLS
INGN

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

Share on Social Networks: